Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hemodialysis thrice weekly Clear all
Completed Not applicable Interventional

Investigating the Effectiveness of Intradialytic Massage on Cramping in Dialysis Patients

NCT01944280
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
massage
Other
Lead sponsor
Catherine Sullivan
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Sep 30, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional

Therapeutic Plantar Electrical Stimulation Intervention During Hemodialysis to Improve Balance and Mobility

NCT05407207
View directory record Official record
Conditions
Diabetes Mellitus, Hemodialysis Complication, Cardiovascular Complication, Quality of Life
Interventions
Tennant Biomodulator ®
Device
Lead sponsor
Hamad Medical Corporation
Industry
Eligibility
40 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Sep 30, 2026, 2:34 AM EDT
Completed No phase listed Observational

Multi-center Study to Investigate the Effects of Citrasate® on Heparin N Requirements During Hemodialysis Treatment

NCT01092455
View directory record Official record
Conditions
Renal Dialysis
Interventions
Heparin N reduction
Drug
Lead sponsor
Randolph Quinn
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
New Haven, Connecticut • New York, New York • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2011 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients

NCT02159859
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Ertapenem
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 88 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dearborn, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01628107
View directory record Official record
Conditions
Chronic Renal Failure Requiring Hemodialysis
Interventions
Epoetin Hospira
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
108
States / cities
Azusa, California • Bellflower, California • Commerce, California + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Impact of Providing High Protein Bar to Dialysis Patients With Low Serum Albumin

NCT00597025
View directory record Official record
Conditions
End Stage Renal Disease, Hypoalbuminemia, Malnutrition
Interventions
Protein Food Bar Intelligent Indulgence
Dietary Supplement
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function

NCT03546205
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
JNJ-64565111
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 79 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Sep 30, 2026, 2:34 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

NCT04064827
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism (SHPT)
Interventions
Paricalcitol
Drug
Lead sponsor
AbbVie
Industry
Eligibility
0 Years to 9 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
14
States / cities
Little Rock, Arkansas • Redwood City, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants

NCT04484857
View directory record Official record
Conditions
Anemia Associated With End Stage Renal Disease
Interventions
Roxadustat
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years and older
Enrollment
283 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Anchorage, Alaska • Pine Bluff, Arkansas • Cerritos, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa

NCT03799627
View directory record Official record
Conditions
Anemia, Dialysis-dependent Chronic Kidney Disease
Interventions
Vadadustat, Epoetin Alfa, Vadadustat TIW
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 99 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Fresno, California • Granada Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

NCT02689206
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863, GSK1278863 matching Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
7
States / cities
Northridge, California • San Dimas, California • Pembroke Pines, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2020 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Not applicable Interventional Results available

Premarket Clinical Safety Assessment of the ELISIO™-HX

NCT07058909
View directory record Official record
Conditions
Renal Failure, Acute Renal Failure, Chronic Renal Failure, Chronic Kidney Diseases, End Stage Renal Disease
Interventions
ELISIO™-HX Dialyzer
Device
Lead sponsor
Nipro Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Empagliflozin in ESKD - A Feasibility Study

NCT05687058
View directory record Official record
Conditions
Kidney Failure, Chronic, Heart Failure
Interventions
Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing, Empagliflozin 10 mg daily dosing
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Liberation From Acute Dialysis

NCT04218370
View directory record Official record
Conditions
Acute Kidney Injury, Kidney; Disease, Acute, Dialysis Related Complication
Interventions
Dialysis
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
San Francisco, California • St Louis, Missouri • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

NCT02260193
View directory record Official record
Conditions
Anemia, End Stage Renal Disease
Interventions
AKB-6548
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
16
States / cities
El Granada, California • Long Beach, California • San Dimas, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2022 · Synced Sep 30, 2026, 2:34 AM EDT
Completed No phase listed Observational

Blood Volume Analysis and Related Outcomes in Hemodialysis

NCT01679249
View directory record Official record
Conditions
End Stage Kidney Disease
Interventions
Not listed
Lead sponsor
VA New York Harbor Healthcare System
Federal
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 30, 2026, 2:34 AM EDT
Active, not recruiting Phase 3 Interventional

Vafseo Outcomes In-Center Experience

NCT06520826
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
Vadadustat, Erythropoiesis Stimulating Agent
Drug
Lead sponsor
USRC Kidney Research
Network
Eligibility
18 Years and older
Enrollment
2,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Lone Tree, Colorado • Dalton, Georgia • Gallup, New Mexico + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

NCT04313153
View directory record Official record
Conditions
Anemia
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Chula Vista, California • Granada Hills, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Not applicable Interventional

Pomegranate and Hemodialysis Pilot Trial

NCT01562340
View directory record Official record
Conditions
End Stage Renal Disease, Cardiovascular Disease, Inflammation
Interventions
Pomegranate juice, Pomegranate fruit extract
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768
View directory record Official record
Conditions
Anemia Associated With Chronic Kidney Disease (CKD)
Interventions
Vadadustat, Mircera®
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
58
States / cities
Huntsville, Alabama • Phoenix, Arizona • Pine Bluff, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function

NCT03874117
View directory record Official record
Conditions
Hemodialysis, Kidney Failure, Chronic
Interventions
Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis, Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Palo Alto, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 30, 2026, 2:34 AM EDT
Recruiting Not applicable Interventional

Incremental Hemodialysis: The TwoPlus Trial

NCT05828823
View directory record Official record
Conditions
End-Stage Kidney Disease
Interventions
Hemodialysis twice weekly, Hemodialysis thrice weekly
Device · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Jacksonville, Florida • Atlanta, Georgia • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 3 Interventional

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients

NCT00561093
View directory record Official record
Conditions
Hypoalbuminemia, Protein-energy Malnutrition, Inflammation, Oxidative Stress, Chronic Kidney Disease (CKD) Hemodialysis
Interventions
pentoxiphylline, Nepro, anti-inflammatory module (similar to Oxepa), Placebo pill imitating pentoxiphylline, Placebo to imitate Nepro, Placebo to imitate anti-inflammatory module (similar to Oxepa)
Drug · Dietary Supplement
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Irvine, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Sep 30, 2026, 2:34 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

NCT01254565
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
KAI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
13
States / cities
Azusa, California • Costa Mesa, California • Lynwood, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Sep 30, 2026, 2:34 AM EDT